Biotechs Brace to Battle a Deadly GI Bacterium
This article was originally published in Start Up
Executive Summary
C. difficile is the number one cause of infectious diahrrea in the developed world. Long thought to be a nuisance, the infections are turning deadly, and a spate of outbreaks has occurred at hospitals in the US, Canada, and Europe. Biotechs are racing to develop new therapeutics to combat the killer bug.
You may also be interested in...
Optimer Looks To Partner C. Diff Candidate After Trial Success
OPT-80’s success in the clinic dramatically improves Optimer’s ability to partner the product for a healthy sum.
Optimer Looks To Partner C. Diff Candidate After Trial Success
OPT-80’s success in the clinic dramatically improves Optimer’s ability to partner the product for a healthy sum.
Optimer Rides High After OPT-80 C. Diff Trial Success
Phase III data show antibiotic non-inferior to Vancocin; additional trial results due mid-2009 with an NDA filing by year’s end.